GeneTex
United States (US)

VEGF antibody [A7-E11-G2]

Cat No. GTX16027

Host Mouse
Clonality Monoclonal
Clone Name A7-E11-G2
Isotype IgG
Application WB, ICC/IF, ELISA
Reactivity Human
APPLICATION

Application Note

We recommend the following starting dilutions: For ELISA: Use at a concentration of 6.25 ng/ml. For WB: Use at a dilution of 1:2000. Optimal dilutions should be determined experimentally by the end user.

Specificity/Sensitivity

The mouse anti-human VEGF antibody specifically detects targets derived from human recombinant protein at various concentrations. Cross reactivity with mouse and rat are expected from sequence similarity.
PROPERTIES

Form

Liquid

Buffer

PBS

Storage

Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.

Concentration

1 mg/ml (Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Immunogen

Recombinant protein derived from human VEGF.

Purification

The IgG fraction of tissue culture supernatant was purified by Protein A/G affinity chromatography.

Conjugation

Unconjugated

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

VEGFA Antibody , MVCD1 Antibody , VPF Antibody , vascular endothelial growth factor A Antibody

Background

This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq, Jul 2008]
REFERENCE
SDS
PBS.pdf
Package List Price ($)
$ 319